Physician profile
Joseph Pirman
NPI 1578566303
$2,402.80
in general payments reported to CMS, 2019-2025
23 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $42.29 · 2021: $177 · 2022: $291 · 2023: $442 · 2024: $576 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $640.23 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Coopervision INC. | $346.42 | 2019-2022 | |
| Oyster Point Pharma, INC. | $174.37 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $146.61 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $137.86 | 2019 | |
| Horizon Therapeutics Plc | $121.33 | 2023 | Tepezza |
| Harrow Eye, LLC | $113.62 | 2024-2025 | Vevye, Iheezo |
| Apellis Pharmaceuticals, INC. | $103.27 | 2023-2025 | Syfovre |
| Dompe US, INC. | $92.79 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $83.52 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $68.80 | 2023-2025 | Miebo, Vyzulta |
| Thea Pharma INC. | $60.81 | 2023-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $51.03 | 2024-2025 | Acthar |
| Shire North American Group INC | $48.15 | 2019 | |
| Abbvie INC. | $42.99 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.48 | 2024 | Tepezza |
| Allergan, INC. | $27.34 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $24.40 | 2024 | Xdemvy |
| Sight Sciences, INC. | $21.82 | 2024 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $20.45 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Ivantis, INC | $18.69 | 2021 | |
| Leadiant Biosciences, INC. | $13.70 | 2023 | Cystaran |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pirman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.